ライフサイエンスコーパス: treatment-resistant

1 -step treatment for those whose symptoms are treatment resistant.

2 ffect, and ~30% of depressed patients remain treatment resistant.

3 f melanoma cells, which are slow-cycling and treatment-resistant.

4 ure T cell cancers are typically aggressive, treatment resistant and associated with poor prognosis.

5 atent microenvironmental differences between treatment-resistant and -sensitive tumors.

6 is were assessed to test the hypothesis that treatment-resistant and non-refractory patients would ex

7 Replicated differences between treatment-resistant and treatment-responsive patients in

8 e than a third of patients with epilepsy are treatment resistant, and thus new, more effective therap

9 We report a rare case of a giant treatment-resistant aneurysm in a 65-year-old woman.

10 CEACAM6 may contribute to the pathology of treatment-resistant asthma via neutrophil and airway epi

11 tment strategies in specific forms of severe treatment-resistant asthma.

12 t episodes, due to deep tissue infection and treatment-resistant bacterial reservoirs.

13 Thirty-nine participants with treatment-resistant BD (23 F, ages 18-65) received a sin

14 with poor control attributed to survival of treatment-resistant biofilm communities.

15 inicians as the most effective treatment for treatment-resistant bipolar depression, but no randomize

16 algorithm-based pharmacological treatment in treatment-resistant bipolar depression.

17 key role in the long-term survival of these, treatment-resistant breast cancer stem cells (CSCs), all

18 ses driving the eco-evolutionary dynamics of treatment-resistant cancer populations.

19 Presence of treatment-resistant cancer stem cells (CSC) may associat

20 ain structures, the regenerative capacity of treatment-resistant cancer stem cells, and challenges in

21 Patients with metastatic and treatment-resistant cancer were prospectively enrolled a

22 ad and neck (SCCHN) is a common, aggressive, treatment-resistant cancer with a high recurrence rate a

23 that thorough molecular characterization of treatment-resistant cancers can identify therapeutic tar

24 itors are used for the treatment of advanced treatment-resistant cancers, and many have also achieved

25 vous system tumors and remain among the most treatment-resistant cancers.

26 uroleptics and neuromodulatory approaches in treatment-resistant cases provides alternatives for pati

27 f pathogenic autoantibodies, particularly in treatment-resistant cases.

28 nd suggest a unique therapeutic approach for treatment-resistant CCNE1-amplified tumors.

29 y and molecular basis for this 'alternative' treatment-resistant cell state remain incompletely under

30 Following doxorubicin treatment, resistant cells accumulated in S phase, which

31 Examples of putative treatment-resistant cells isolated in small topographica

32 we present these nonmedication approaches to treatment-resistant childhood epilepsy, with attention t

33 , double-blind, placebo-controlled study, 60 treatment-resistant children and adolescents (mean age=1

34 kout mice, including neurodegeneration and a treatment-resistant choreoathetoid movement disorder.

35 ontrol subjects, with even lower activity in treatment resistant chronic SCZ patients, implicating ND

36 ssors increases the likelihood of developing treatment-resistant, chronic psychological problems, inc

37 acking clonal evolution and the emergence of treatment-resistant clones.

38 rectal tissues collected from patients with treatment-resistant Crohn's disease who participated in

39 rapid antidepressant action in depressed and treatment-resistant depressed patients within hours.

40 ine produces rapid antidepressant actions in treatment-resistant depressed patients.

41 Forty treatment-resistant depressed unipolar patients with Ham

42 rmacotherapy) for primary care patients with treatment resistant depression compared with usual care

43 Treatment resistant depression is, by definition, diffic

44 rrently underappreciated means of addressing treatment resistant depression with the potential to att

45 Eligible patients were aged 18-65 years with treatment-resistant depression (Hamilton Depression Rati

46 ion for adults aged older than 60 years with treatment-resistant depression (Montgomery Asberg Depres

47 ticity and reduces cognitive difficulties in treatment-resistant depression (TRD) and remitted BD.

48 Patients with treatment-resistant depression (TRD) do not respond suff

49 stimulation (DBS) as a putative approach for treatment-resistant depression (TRD) has now been resear

50 t effects of deep brain stimulation (DBS) in treatment-resistant depression (TRD) have been demonstra

51 Treatment-resistant depression (TRD) is prevalent and as

52 essed prevention of relapse in patients with treatment-resistant depression (TRD) taking olanzapine/f

53 changes in 34 individuals (ages 18-65) with treatment-resistant depression (TRD) who received a sing

54 ms in approximately 40%-60% of patients with treatment-resistant depression (TRD), but data on long-t

55 l trials of deep brain stimulation (DBS) for treatment-resistant depression (TRD), including those ta

56 cs and innovative treatments--especially for treatment-resistant depression (TRD)--are essential.

57 ment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD).

58 not respond to conventional ADs and develop treatment-resistant depression (TRD).

59 e intravenous (IV) infusion in patients with treatment-resistant depression (TRD).

60 rapy (MST) is a novel therapeutic option for treatment-resistant depression (TRD).

61 5-HTP can confer antidepressant response in treatment-resistant depression (TRD).

62 doses of IV ketamine among outpatients with treatment-resistant depression (TRD).

63 apid antidepressant effects in patients with treatment-resistant depression (TRD).

64 eases, so we assessed their association with treatment-resistant depression (TRD).

65 subanesthetic dose of ketamine infusion for treatment-resistant depression (TRD).

66 apid antidepressant effects in patients with treatment-resistant depression (TRD); however, the poten

67 or the safety and efficacy of psilocybin for treatment-resistant depression and motivates further tri

68 he dose-related efficacy of R/S-ketamine for treatment-resistant depression and the first to characte

69 subcallosal cingulate DBS as a treatment for treatment-resistant depression but did not show statisti

70 Forty-one participants with treatment-resistant depression completed a single-site r

71 n current evidence, ketamine use for severe, treatment-resistant depression does not violate ethical

72 ressant effects of ketamine in patients with treatment-resistant depression drawn from a Chinese popu

73 (2) receptor function in clinical trials for treatment-resistant depression either alone or in combin

74 ficacy and safety of switching patients with treatment-resistant depression from an ineffective antid

75 Current treatment options for treatment-resistant depression have considerable limitat

76 stimulation implantation surgery for chronic treatment-resistant depression in a randomized and blind

77 therefore is not an option for patients with treatment-resistant depression in routine clinical pract

78 This suggests that an immune signature of treatment-resistant depression is already present at bas

79 opment of improved treatments especially for treatment-resistant depression is desired.

80 he potential benefit of this cell therapy on treatment-resistant depression is unknown.

81 erformance indicates which older adults with treatment-resistant depression may respond favorably to

82 target-based neuromodulation strategies for treatment-resistant depression patients.

83 Twenty-two participants with treatment-resistant depression received open-label SAINT

84 The Treatment-Resistant Depression Registry investigated whe

85 f >/=18 and a Massachusetts General Hospital Treatment-Resistant Depression staging score of 2-10) an

86 Participants with treatment-resistant depression were implanted with a DBS

87 -blind study, adults (ages 18-64 years) with treatment-resistant depression were randomized to receiv

88 erior mid-cingulate cortex, 20 patients with treatment-resistant depression who had not received surg

89 d 94 volunteers, comprising 15 patients with treatment-resistant depression who had received bilatera

90 y representative population of patients with treatment-resistant depression within the NHS and theref

91 To test the safety and efficacy of DBS for treatment-resistant depression, a prospective, randomise

92 t naturalistic study of efficacy outcomes in treatment-resistant depression, and it provides addition

93 patients with major depressive disorder have treatment-resistant depression, defined as no adequate r

94 ive therapies, especially those designed for treatment-resistant depression, has been sorely needed.

95 for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively.

96 Trials recruiting participants with treatment-resistant depression, treatment duration of le

97 highlight EPO as an interesting compound for treatment-resistant depression, which deserves further i

98 ient antidepressant effects in patients with treatment-resistant depression, which may be prolonged b

99 r imaging, were acquired in 16 patients with treatment-resistant depression, who then received SCC DB

100 ts are insufficient for clinical response in treatment-resistant depression.

101 n surgical targeting in 11 participants with treatment-resistant depression.

102 ations in off-label ketamine use for severe, treatment-resistant depression.

103 tial antidepressant effects in patients with treatment-resistant depression.

104 cacy of psilocybin in patients with unipolar treatment-resistant depression.

105 over 3-5 years in primary care patients with treatment-resistant depression.

106 onset antidepressant effect in patients with treatment-resistant depression.

107 nically relevant population of patients with treatment-resistant depression.

108 by the U.S. Food and Drug Administration for treatment-resistant depression.

109 ion of contacts in long-term stimulation for treatment-resistant depression.

110 potent antidepressant effects of ketamine in treatment-resistant depression.

111 d included 73 bipolar disorder patients with treatment-resistant depression.

112 id antidepressant responses in patients with treatment-resistant depression.

113 f the reward system in DBS for patients with treatment-resistant depression.

114 binant human EPO improves mood and memory in treatment-resistant depression.

115 apid antidepressant effects in patients with treatment-resistant depression.

116 ising antidepressant efficacy for adolescent treatment-resistant depression.

117 a Phase II clinical development program for treatment-resistant depression.

118 ctivity MRI (fcMRI)-guided iTBS protocol for treatment-resistant depression.

119 re considered as a promising animal model of treatment-resistant depression.

120 idly acting antidepressant for patients with treatment-resistant depression.

121 ion strategies for ketamine in patients with treatment-resistant depression.

122 enrolled in a clinical trial of SCC DBS for treatment-resistant depression.

123 ) = 303; n(dystonia) = 64; n(tremor) = 39; n(treatment-resistant depression/anorexia nervosa) = 76) t

124 Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopat

125 would also specifically target the typically treatment-resistant disease associated with TP53 mutatio

126 redict treatment resistance, suggesting that treatment-resistant disease might be a distinct subtype

127 ARID1A mutations are more frequent in treatment-resistant disease, and our findings provide me

128 early 10% of people with asthma have severe, treatment-resistant disease, which is frequently associa

129 p53 function is often impaired in relapsed, treatment-resistant disease.

130 e extensive medical therapy and some develop treatment-resistant disease.

131 ability, abnormal neurological findings, and treatment-resistant epilepsy (in two of four).

132 blation procedures however, individuals with treatment-resistant epilepsy frequently exhibit heteroge

133 Treatment-resistant epilepsy is a common and debilitatin

134 ) with severe, intractable, childhood-onset, treatment-resistant epilepsy, who were receiving stable

135 l disorder defined by temperature-sensitive, treatment-resistant epilepsy-and record activity of puta

136 mains a standard of therapy in patients with treatment-resistant epilepsy.

137 ile in children and young adults with highly treatment-resistant epilepsy.

138 fficacious in children and young adults with treatment-resistant epilepsy.

139 Compulsive alcohol consumption is a core, treatment-resistant feature of alcohol use disorder.

140 psy can also be appreciated in patients with treatment-resistant focal epilepsy who are treated with

141 pared with placebo as adjunctive therapy for treatment-resistant focal-onset seizures in tuberous scl

142 ost a third of patients with epilepsy have a treatment-resistant form, which is associated with sever

143 for depression and anxiety in traditionally treatment-resistant groups, including AN.

144 ST2 values were 2.3 times as likely to have treatment-resistant GVHD (95% confidence interval [CI],

145 rmine the association of this biomarker with treatment-resistant GVHD and 6-month mortality after tre

146 fter exclusions, 151 patients with advanced, treatment-resistant head and neck tumors, including squa

147 fter exclusions, 151 patients with advanced, treatment-resistant head and neck tumors, including squa

148 ve pressures influencing the dynamics of the treatment-resistant HIV reservoir.

149 T imaging in treatment-sensitive COLO205 and treatment-resistant HT29 human colorectal cancer xenogra

150 T imaging in treatment-sensitive COLO205 and treatment-resistant HT29 human colorectal cancer xenogra

151 py, are used in clinical practice for severe treatment resistant hypertension in some countries.

152 h cardiovascular risk, in patients with true-treatment resistant hypertension, whereas it only affect

153 (Renal Denervation in Treatment Resistant Hypertension; NCT01687725).

154 study, there were 54 patients with moderate treatment-resistant hypertension (office BP >/=140/90 mm

155 of renal denervation (RDN) in patients with treatment-resistant hypertension according to the establ

156 ut not the efficacy of renal denervation for treatment-resistant hypertension at 6 months post proced

157 thelin receptor antagonists, particularly in treatment-resistant hypertension, chronic kidney disease

158 distributed cohort of veterans with apparent treatment-resistant hypertension, testing for primary al

159 after RDN persist long term in patients with treatment-resistant hypertension, with good safety.

160 eed for improved management of patients with treatment-resistant hypertension.

161 n muscle glucose metabolism in patients with treatment-resistant hypertension.

162 ally reduces blood pressure in patients with treatment-resistant hypertension.

163 Primary aldosteronism is a common cause of treatment-resistant hypertension.

164 enal injury often lead to the development of treatment-resistant hypertension.

165 All participants were treatment resistant (ie, had used illicit or non-prescri

166 Compared with non-refractory patients, treatment-resistant individuals exhibited reduced connec

167 ostriatal connectivity was more pervasive in treatment-resistant individuals.

168 e conversion of radiosensitive non-GICs into treatment-resistant, induced GICs (iGICs).

169 with missense variants, often manifesting as treatment-resistant infantile epileptic encephalopathy.

170 notherapy; however, some subjects experience treatment-resistant inflammation or adverse reactions to

171 Remission of treatment-resistant late-life depression (defined as a M

172 of aripiprazole augmentation for first-line treatment-resistant late-life depression (Incomplete Res

173 phorylation, a process that is suppressed in treatment-resistant leukemic cells.

174 ration and migration of PCa cells, including treatment resistant lines, and suppressed tumor cell pro

175 Treatment-resistant major depression is common and poten

176 ix women) with moderate-to-severe, unipolar, treatment-resistant major depression received two oral d

177 rapid and prolonged antidepressant effect in treatment-resistant major depression.

178 ver trial of ketamine in 33 individuals with treatment-resistant major depressive disorder (TRD) and

179 t, has been approved by the FDA for treating treatment-resistant major depressive disorder (TRD) in 2

180 uropsychological outcome of 25 patients with treatment-resistant major depressive disorder (TRD) who

181 e imaging study with 40 patients with highly treatment-resistant major depressive disorder and never-

182 Primary outcome criterion was severity of treatment-resistant major depressive disorder as assesse

183 A total of 41 subjects with treatment-resistant major depressive disorder underwent

184 L-6 in two separate cohorts of patients with treatment-resistant major depressive disorder.

185 owing open-label celecoxib administration in treatment-resistant major depressive disorder.

186 ent of novel therapeutics, in particular for treatment-resistant major depressive disorder.

187 Although melanoma is a historically treatment-resistant malignancy, in recent years unpreced

188 e central role of AR and REST in classifying treatment-resistant mCRPC phenotypes.

189 Twenty-eight medication-free inpatients with treatment-resistant MDD and 16 healthy controls (HCs) pa

190 bo-controlled study, 22 subjects with DSM-IV treatment-resistant MDD received a single infusion of ei

191 In patients with treatment-resistant MDD, a single intravenous dose of th

192 0RSK inhibition as a therapeutic strategy in treatment-resistant melanoma and provide insight into th

193 We analyzed the primary tumor, the sole treatment-resistant metastasis, and germline tissue to e

194 Preliminary evidence of activity in treatment-resistant metastatic breast cancer requires co

195 matergic modulator ketamine are effective in treatment-resistant mood disorders, underscoring the pot

196 dels, with highly glycolytic tumors becoming treatment resistant more rapidly than poorly glycolytic

197 COV2) to reduce the risk of the emergence of treatment-resistant mutant virus.

198 rd detection thresholds, frequently harbored treatment-resistant mutations, and were more common in s

199 ive (N=40), and patients whose symptoms were treatment resistant (N=37), as well as healthy control s

200 medication (n=9); or (2) treatment response: treatment resistant (n=5) or treatment responsive (n=4).

201 treal aflibercept is effective in previously treatment-resistant neovascular AMD.

202 An in vivo mouse model of high-risk treatment-resistant neuroblastoma exhibits changes in th

203 apy for well-screened patients with specific treatment-resistant neuropsychiatric diseases.

204 our activity in patients with progressive or treatment-resistant NSCLC, providing a rationale for fur

205 served as a last-resort treatment for severe treatment-resistant obsessive-compulsive disorder (OCD).

206 ising therapeutic approach for patients with treatment-resistant obsessive-compulsive disorder, a con

207 stimulation, and neurosurgical ablation for treatment-resistant OCD.

208 , as an adjunctive therapy for children with treatment-resistant OCD.

209 ent (escitalopram: 20 mg per 12 weeks) in 11 treatment-resistant older adults with major depression;

210 designated as having 'difficult to treat', 'treatment-resistant' or 'refractory' RA.

211 excluded studies that focused exclusively on treatment-resistant patient populations defined within t

212 pid-acting antidepressant, effective even in treatment resistant patients.

213 not differ from that of control subjects in treatment-resistant patients (p > .3).

214 pared with standard therapy alone at helping treatment-resistant patients abstain from using illicit

215 ed for symptom severity levels by recruiting treatment-resistant patients currently showed low sympto

216 ntify all neuroimaging studies that examined treatment-resistant patients or longitudinally assessed

217 However, in this study, the treatment-resistant patients were highly symptomatic, wh

218 apid and prolonged antidepressant effects in treatment-resistant patients with major depressive disor

219 c analysis of [(18)F]FDOPA PET to fast-track treatment-resistant patients with schizophrenia to cloza

220 ologic medications are increasingly given to treatment-resistant patients, but they can represent hig

221 In addition, among treatment-resistant patients, new mutations were acquire

222 s that could be therapeutically exploited in treatment-resistant patients.

223 ely sustained antidepressant action, even in treatment-resistant patients.

224 ntidepressant drugs and reduce the number of treatment-resistant patients.

225 and sustained antidepressant actions even in treatment-resistant patients.

226 erotonin reuptake inhibitors (SSRIs) in some treatment-resistant patients; however, it is not known w

227 Of note, treatment-resistant plasma cells contained a substantial

228 positively correlated with the frequency of treatment-resistant plasma cells in the bone marrow.

229 In a severely treatment-resistant population, this open-label study su

230 ted therapy by increasing the probability of treatment-resistant populations.

231 AR-independent treatment-resistant prostate cancer is a major unresolve

232 ss of compounds with the potential to combat treatment-resistant prostate cancer.

233 occurs in approximately 15%-20% of advanced treatment-resistant prostate cancers, and this may manif

234 deep brain stimulation in four patients with treatment-resistant psychiatric disease.

235 me points, reminiscent of chronic anxiety in treatment-resistant PTSD.

236 detection and phenotypic characterization of treatment-resistant residual disease.

237 n the chronic schizophrenia (79 regions) and treatment-resistant schizophrenia (106 regions) groups,

238 clozapine and other antipsychotics for both treatment-resistant schizophrenia (TRS) and non-resistan

239 The clinical, social, and economic burden of treatment-resistant schizophrenia (TRS) are substantial.

240 ation-based cohort of 2,370 individuals with treatment-resistant schizophrenia after Jan.

241 r 6 months of treatment for 33 patients with treatment-resistant schizophrenia and 31 controls, and p

242 A total of 33 patients with treatment-resistant schizophrenia and 31 healthy control

243 chronic schizophrenia, and 47 patients with treatment-resistant schizophrenia and in matching health

244 clozapine treatment, in 552 individuals with treatment-resistant schizophrenia and robustly inferred

245 s that a different neurobiology may underlie treatment-resistant schizophrenia and that dopamine synt

246 Identification of patients at high risk of treatment-resistant schizophrenia at the time of schizop

247 hing treatment to clozapine in patients with treatment-resistant schizophrenia compared with healthy

248 Patients with treatment-resistant schizophrenia display progressive su

249 Up to 70% of patients with treatment-resistant schizophrenia do not respond to cloz

250 ients fulfilled the main proxy definition of treatment-resistant schizophrenia during a median follow

251 Patients with treatment-resistant schizophrenia had an excess of rare

252 antipsychotic among adults with evidence of treatment-resistant schizophrenia in routine clinical pr

253 some of the neurobiological changes seen in treatment-resistant schizophrenia lie along a continuum

254 higher mortality rate among individuals with treatment-resistant schizophrenia not treated with cloza

255 The prevalence of treatment-resistant schizophrenia points to a discrete i

256 We used a treatment-based proxy for treatment-resistant schizophrenia to identify candidate

257 Our main proxy definition of treatment-resistant schizophrenia was the earliest insta

258 chotic is more efficacious for patients with treatment-resistant schizophrenia, and blinded RCTs-in c

259 ozapine is the only effective medication for treatment-resistant schizophrenia, but its worldwide use

260 In treatment-resistant schizophrenia, clozapine is consider

261 clozapine, the only licensed medication for treatment-resistant schizophrenia, is under-prescribed a

262 with clozapine treatment in individuals with treatment-resistant schizophrenia.

263 antipsychotic treatments and this is termed treatment-resistant schizophrenia.

264 ity was significantly lower in patients with treatment-resistant schizophrenia.

265 be included in future prediction models for treatment-resistant schizophrenia.

266 .39]) were all significantly associated with treatment-resistant schizophrenia.

267 pisode psychosis, chronic schizophrenia, and treatment-resistant schizophrenia.

268 in the clinical management of patients with treatment-resistant schizophrenia.

269 pathophysiology of treatment-responsive and treatment-resistant schizophrenia.

270 ntrations in a large sample of patients with treatment-resistant schizophrenia.

271 ess duration = 1 year), 63 individuals with 'treatment-resistant' schizophrenia (mean illness duratio

272 Similarly, individuals with 'treatment-resistant' schizophrenia had higher levels of

273 65 years with tuberous sclerosis complex and treatment-resistant seizures (>/=16 in an 8-week baselin

274 patients with tuberous sclerosis complex and treatment-resistant seizures.

275 of medical therapy, but 2 patients developed treatment-resistant SLE, and we decided to pursue treatm

276 in the induction and/or maintenance of this treatment-resistant state.

277 1)R mechanisms may have an essential role in treatment-resistant stimulant abuse, suggesting new appr

278 isolated single cells and small clusters of treatment-resistant subclones.

279 our entire research population, but also in treatment-resistant subgroups and subgroups with a histo

280 Treatment-resistant subjects had significantly higher TH

281 Eighty treatment-resistant subjects who met DSM-IV criteria for

282 strated neurosensory macular detachment with treatment-resistant submacular fluid and vitelliform mat

283 of glioblastoma (GBM) is driven in part by a treatment-resistant subpopulation of GBM stem cells (GSC

284 induced asparaginase sensitivity in distinct treatment-resistant subtypes of acute leukemia, but not

285 may prove to be an effective therapeutic for treatment-resistant symptoms of mental illness.

286 apid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders.

287 Patients with treatment-resistant symptoms showed the highest white ma

288 tion was significantly stronger than that in treatment-resistant SZ subjects or in NCs.

289 (NCs, n=13) vs subjects with SZ (n=25); NC, treatment-resistant SZ, and treatment-responsive SZ; and

290 Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MC

291 cant physical disabilities (n = 100, 64.1%), treatment-resistant tuberculosis (TB) (n = 32, 20.5%), c

292 Genomically, the treatment-resistant tumor uniquely harbored biallelic PT

293 The majority of advanced, treatment-resistant tumors across tumor types harbor bio

294 sion of TRIP13 in SCCHN leads to aggressive, treatment-resistant tumors and enhanced repair of DNA da

295 In the treatment-resistant tumors we noted the emergence of CD3

296 es as well as contribute to the evolution of treatment-resistant tumour cells.

297 ient antidepressant effects in patients with treatment resistant unipolar depression (TRD).

298 loidosis should be considered in atypical or treatment resistant, upper or lower chronic gastrointest

299 tify the evolutionary dynamics of these post-treatment resistant variant populations.

300 ive antiviral strategy to avoid selection of treatment-resistant variants, and inhibitors of autophag